Carriers of certain gene mutations are at greater risk of developing breast cancer if exposed to chest X-rays, research has shown.
A breast cancer drug has been pulled from NHS treatment because it was not proving cost-effective, the National Institute for Health and Clinical Excellence (NICE) has reported.
The National Institute for Health and Clinical Excellence, (NICE), has opened a consultation on draft guidance which does not recommend bevacizumab (Avastin, Roche), for metastatic breast cancer, when used in combination with the chemotherapy drug, capecitabine....
Two more cancer drugs have been provisionally banned for NHS after it was decided they were too expensive for the potential results.
The PIP breast implant furore could prompt the creation of an insurance scheme for cosmetic surgery patients to prevent similar remedial problems in the future.
The National Institute for Health and Clinical Excellence (Nice) has banned another breast cancer drug from routine NHS use.
Aviva has added the first partial payments to its critical illness (CI) policy and halved the length of time for a Multiple Sclerosis (MS) claim.
The National Institute for Health and Clinical Excellence (NICE) has rejected another cancer drug for the NHS due to its cost.
The NHS exceeded all seven of its targets for cancer diagnosis and treatment during the last year, new data has revealed.
Bright Grey and Scottish Provident have sought to clarify breast cancer cover from critical illness (CI) providers following recent changes made to their definitions.